Adverum Biotechnologies Announces Long-term Preclinical Efficacy Data on ADVM-022 Gene Therapy in Wet AMD – GlobeNewswire (press release)
EconoTimes |
Adverum Biotechnologies Announces Long-term Preclinical Efficacy Data on ADVM-022 Gene Therapy in Wet AMD
GlobeNewswire (press release) MENLO PARK, Calif., May 01, 2018 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, announced long-term preclinical efficacy data on … Adverum Biotechnologies (ADVM) Reports LT Preclinical Efficacy Data on ADVM-022 Gene Therapy in Wet AMD |
